Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations

OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare disease that is currently considered a low-grade neoplasm with metastatic potential and variable progression. Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Freitas, Carolina Salim Gonçalves, Baldi, Bruno Guedes, Araújo, Mariana Sponholz, Heiden, Glaucia Itamaro, Kairalla, Ronaldo Adib, Carvalho, Carlos Roberto Ribeiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Pneumologia e Tisiologia 2015
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541764/
https://www.ncbi.nlm.nih.gov/pubmed/26176526
http://dx.doi.org/10.1590/S1806-37132015000004553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541764/
https://www.ncbi.nlm.nih.gov/pubmed/26176526
http://dx.doi.org/10.1590/S1806-37132015000004553

Ejemplares similares